China’s WuXi Buys Bristol Myers Squibb’s Swiss Plant
China contract development and manufacturing organization (CDMO) WuXi STA has agreed to buy Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland, for an undisclosed sum. The site will be WuXi STA’s first facility in Europe. The transaction is expected to complete during the second quarter, subject to the usual conditions and regulatory approvals.
“The acquisition will allow WuXi STA to better serve European markets and support our global customers to deliver innovative medicines and treatments to patients around the world,” said WuXi STA’s CEO Minzhang Chen.
Lou Schmukler, president of global product development and supply at Bristol Myers Squibb, added: “This is an important step in the ongoing evolution of our manufacturing network to support our product portfolio. Switzerland remains an important strategic location for Bristol Myers Squibb, and we look forward to maintaining a strong presence in the Neuchâtel area.”
The facility located in the Swiss canton of Neuchâtel has commercial-scale production capacity for capsule and tablet dosage forms and was designed to accommodate future growth.
WuXi STA is a subsidiary of WuXi AppTec and operates four plants in China at Wuxi City, Jiangsu; Jinshan, Shanghai; Changzhou, Jiangsu; and Shanghai Waigaoqiao Free Trade Zone, plus another in San Diego, California, USA.
Author: Ellaine Burridge, Freelance Journalist
